StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

Analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of AKTX stock opened at $1.29 on Thursday. Akari Therapeutics has a 12-month low of $0.90 and a 12-month high of $4.40. The firm’s 50 day moving average is $1.17 and its 200 day moving average is $2.33.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.